Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases
Trends in Biotechnology · 2024-11 · 42 (11) · 1439-1452
DOI: 10.1016/j.tibtech.2024.05.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2024-11. Verfasst von Yiming Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liangzhu Laboratory, Zhejiang University Medical Center and Zhejiang Provincial Key Lab of Ophthalmology, Eye Center of The Second Affiliated Hospita…. Hauptthemen laut MEDLINE: Eye Diseases, Nanomedicine, RNA. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 96 Literaturangaben.
Abstract (Originalsprache)
Ocular disorders remain a major global health challenge with unmet medical needs. RNA nanomedicine has shown significant therapeutic benefits and safety profiles in patients with complex eye disorders, already benefiting numerous patients with gene-related eye disorders. The effective delivery of RNA to the unique structure of the eye is challenging owing to RNA instability, off-target effects, and ocular physiological barriers. Specifically tailored RNA medication, coupled with sophisticated engineered delivery platforms, is crucial to guide and advance developments in treatments for oculopathy. Herein we review recent advances in RNA-based nanomedicine, innovative delivery strategies, and current clinical progress and present challenges in ocular disease therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liangzhu Laboratory, Zhejiang University Medical Center and Zhejiang Provincial Key Lab of Ophthalmology, Eye Center of The Second Affiliated Hospital, Zhejiang University, Hangzhou, China; Center for Nanomedicine and D…
- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: wtao@bwh.harvard.edu.
- Liangzhu Laboratory, Zhejiang University Medical Center and Zhejiang Provincial Key Lab of Ophthalmology, Eye Center of The Second Affiliated Hospital, Zhejiang University, Hangzhou, China. Electronic address: xlren@zju…
Zitieren
APA
Zhang, Y., Shi, Y., Khan, M. M., Xiao, F., Chen, W., Tao, W., Yao, K., & Kong, N. (2024). Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases. Trends in Biotechnology, 42(11), 1439-1452. https://doi.org/10.1016/j.tibtech.2024.05.002
Vancouver
Zhang Y, Shi Y, Khan MM, Xiao F, Chen W, Tao W, et al. Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases. Trends in Biotechnology. 2024;42(11):1439-1452. doi:10.1016/j.tibtech.2024.05.002
BibTeX
@article{Zhang2024,
author = {Zhang, Yiming and Shi, Yesi and Khan, Muhammad M and Xiao, Fan and Chen, Wei and Tao, Wei and Yao, Ke and Kong, Na},
title = {Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases},
journal = {Trends in Biotechnology},
year = {2024},
volume = {42},
number = {11},
pages = {1439--1452},
doi = {10.1016/j.tibtech.2024.05.002}
}
EUVIMED